Business Context and Reporting Period
This Form 8-K is filed by Mainz Biomed N.V. (trading symbol QUCY) on April 9, 2026. The registrant is an emerging growth company incorporated in the Netherlands with principal executive offices in Mainz, Germany. The filing addresses a strategic pivot to focus on pancreatic cancer screening and post-quantum cybersecurity, alongside a resolution of Nasdaq listing compliance issues.
Key Financial Metrics and Liquidity
- Equity Investment: The company received $3 million on February 13, 2026, for the first tranche of preferred shares and a pre-payment of an additional $3 million in March 2026 for a second tranche, totaling $6 million in recent equity capital.
- Asset Sale Proceeds: The company entered into an agreement to sell "Next Gen IP" for $1.25 million, with closing expected by April 23, 2026.
- Stockholders' Equity: As of the 2025 year-end, stockholders' equity was $641,600. Management believes current equity now exceeds the $2.5 million Nasdaq minimum requirement due to the $6 million investment.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the current period.
Material Changes
- Strategic Wind-Down: In February 2026, the board decided to wind down the ColoAlert product and the development of next-generation colorectal cancer screening products to reduce monthly expenditures and refocus resources.
- Asset Disposition: On March 28, 2026, the ColoAlert intellectual property was sold. On April 9, 2026, an agreement was signed to sell the remaining "Next Gen IP" for $1.25 million.
- Listing Compliance: The company previously failed to meet the $2.5 million stockholders' equity requirement for Nasdaq listing. The recent $6 million capital raise is intended to restore compliance.
Outlook, Risks, and Management Commentary
- Future Focus: Operations will continue to pursue the pancreatic cancer detection product candidate and explore post-quantum cybersecurity opportunities.
- Use of Proceeds: Net proceeds from the IP sale will be used for settling outstanding liabilities and general corporate purposes.
- Closing Conditions: The $1.25 million IP sale is contingent on standard closing conditions, third-party consents, shipment of samples, and patent application deadline extensions.
- Risk Mitigation: Management asserts that the combination of the equity raise and reduced expenditures from the wind-down has resolved the immediate listing deficiency.
Investor Verification Checklist
- Confirm the closing of the $1.25 million Next Gen IP sale by the April 23, 2026 deadline.
- Verify the updated stockholders' equity balance to ensure continued compliance with Nasdaq Listing Rule 5550(b)(1).
- Monitor the status of the second tranche preferred share issuance to ensure the full $3 million is finalized.
- Review the specific terms of the wind-down regarding employee terminations and liability settlements.